Scarica l'app Stockscreener
167.55
1.84%
-3.14
Dopo l'orario di chiusura:
167.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$170.69
Aprire:
$168.97
Volume 24 ore:
808.81K
Relative Volume:
1.39
Capitalizzazione di mercato:
$8.45B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-25.66
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-8.26%
1M Prestazione:
+13.55%
6M Prestazione:
+54.55%
1 anno Prestazione:
+102.92%
Intervallo 1D:
$165.75
$170.59
Intervallo di 1 settimana:
$165.75
$183.33
Portata 52W:
$79.19
$184.40
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
167.55 | 8.60B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
How interest rate cuts could boost Axsome Therapeutics Inc. stock2025 Pullback Review & Weekly Top Performers Watchlists - ulpravda.ru
Why Axsome Therapeutics Inc. stock could outperform in 2025Quarterly Market Summary & Daily Entry Point Trade Alerts - ulpravda.ru
Can Axsome Therapeutics Inc. (19X) stock hold up in economic slowdown2025 Historical Comparison & Expert Approved Momentum Ideas - ulpravda.ru
How Axsome Therapeutics Inc. stock reacts to Fed rate cutsBreakout Watch & Fast Gain Swing Alerts - ulpravda.ru
Why Axsome Therapeutics Inc. stock is rated strong buyJuly 2025 Reactions & Smart Allocation Stock Tips - ulpravda.ru
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Earns "Equal Weight" Rating from Morgan Stanley - MarketBeat
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - MarketBeat
Morgan Stanley Downgrades Axsome Therapeutics to Equal Weight From Overweight, Adjusts PT to $204 From $196 - MarketScreener
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Morgan Stanley downgrades Axsome stock after 23% rally, raises price target - Investing.com Canada
Axsome therapeutics CEO sells $23.8m in shares By Investing.com - Investing.com UK
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) CEO Sells 29,450 Shares of Stock - MarketBeat
Herriot Tabuteau Sells 31,261 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Equities Analysts Set Expectations for AXSM Q2 Earnings - MarketBeat
UBS Adjusts Price Target on Axsome Therapeutics to $248 From $163, Maintains Buy Rating - MarketScreener
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
H.C. Wainwright raises Axsome Therapeutics stock price target on FDA priority review - Investing.com Canada
Axsome Therapeutics (AXSM) Stock Analysis: Revenue Growth Soars Amid Biotech Innovations - DirectorsTalk Interviews
AXSM: HC Wainwright & Co. Raises Price Target to $200 and Mainta - GuruFocus
Stanley Laman Group Ltd. Makes New $2.13 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics - The Pharma Letter
Axsome Therapeutics Insider Sold Shares Worth $6,206,969, According to a Recent SEC Filing - MarketScreener
Why Axsome Therapeutics (AXSM) Is Up 17.5% After Dual FDA Boosts For AXS-05 And AXS-12 – And What's Next - Yahoo Finance
Axsome Therapeutics (AXSM): Reassessing Valuation After Key FDA Milestones for AXS-05 and AXS-12 - Yahoo Finance
Axsome therapeutics director Saad sells $6.2m in shares By Investing.com - Investing.com Canada
Mark Saad Sells 37,577 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Glaukos (GKOS) - The Globe and Mail
A Comprehensive Guide To Axsome: Unlocking The Potential Of Innovative Therapeutics- - shababeek.org
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation - Finviz
Truist Securities reiterates Buy rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome (AXSM) Stock Jumps 22.8%: Will It Continue to Soar? - Yahoo Finance
Deutsche Bank Raises Price Target on Axsome Therapeutics to $223 From $186, Keeps Buy Rating - MarketScreener
FDA grants Axsome’s AXS-05 sNDA priority review designation - The Pharma Letter
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation - ts2.tech
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug - ts2.tech
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Axsome Advances AXS-12 Toward NDA Filing for Narcolepsy - The Globe and Mail
Axsome (AXSM) Stock; Climbs Nearly 23% After FDA Accelerates Alzheimer’s Review - CoinCentral
Moody Aldrich Partners LLC Trims Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing - ts2.tech
Axsome wins FDA priority review for Auvelity in Alzheimer’s disease agitation - MSN
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review - ts2.tech
FDA supports Axsome’s NDA submission for narcolepsy drug AXS-12 By Investing.com - Investing.com Nigeria
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 - The Globe and Mail
Axsome Therapeutics Stock Skyrockets: What’s Next? - StocksToTrade
Axsome stock jumps nearly 23% after FDA fast-tracks AXS-05 for Alzheimer’s agitation - ts2.tech
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - AOL.com
Key Takeaways - StocksToTrade
Axsome’s Surprising Surge: What’s Next ? - timothysykes.com
From Haiti to Wall Street to Big Pharma: Herriot Tabuteau is on a $6B mission to heal the brain - AOL.com
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):